About ReCode Therapeutics
We are a clinical-stage genetic medicines company founded in 2015, focusing on genetic medicines within Biotechnology Research.
We use our Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to precisely deliver genetic medicines to target organs and cells beyond the liver. This platform supports our development of mRNA and gene correction therapeutics.
We develop therapeutics for genetically defined diseases with limited or no existing treatment options. Our pipeline includes rare disease therapeutics using optimized mRNA and gene correction with redosing capability. The SORT LNP platform is a modular technology that can package and deliver a range of genetic medicines through various routes of administration.
Our lead programs focus on primary ciliary dyskinesia (PCD) and cystic fibrosis (CF). For PCD, we are developing an mRNA-based therapy to restore ciliary function in the lungs of individuals with pathogenic mutations in the DNAI1 gene. For CF, we are addressing the underlying causes of the disease through both mRNA therapy and gene correction approaches.
We are also expanding our pipeline to explore potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver, and infectious diseases.
Mission & Values
Our mission is to enable individuals with genetic diseases to benefit from genetic medicines. Our mRNA and gene correction therapeutics aim to make this a reality.
Our values include:
- Patients First: We strive to deliver impactful medicines to patients in need.
- Solve Together: We collaborate with shared trust and camaraderie.
- Be Curious. Be Kind. Be Yourself.: We embrace a culture of exploration and belonging.
- Act with Urgency: We move expediently and efficiently through thoughtful actions.
- Think It. Own It. Do It.: We encourage autonomy to drive positive change.
- Generate Audacious Science: We innovate through science.
Team & Culture
We have 11-50 employees and look for team members who recognize their potential and the future of genetic medicine. Our culture is one of exploration and belonging, where we encourage team members to bring diverse perspectives and new ideas. Our work environment emphasizes collaboration, focusing on work that supports individuals in living beyond the constraints of their genetic disease. We emphasize shared trust, camaraderie, and a motivation to make a meaningful difference for patients with rare diseases.
Frequently Asked Questions
ReCode Therapeutics is a clinical-stage genetic medicines company that develops mRNA and gene correction therapeutics. These are designed for genetically defined diseases with limited or no current treatment options. The company’s core technology is its Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform, which facilitates targeted delivery of these medicines.
ReCode Therapeutics’ approach involves creating precision genetic medicines using optimized mRNA and gene correction with redosing capabilities. Their SORT LNP platform allows for highly targeted delivery of these medicines to specific organs, tissues, and cells beyond the liver, aiming to overcome limitations of previous delivery systems.
ReCode Therapeutics’ lead programs are focused on developing treatments for cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). For CF, they are exploring both mRNA therapy and gene correction. For PCD, they are developing an mRNA-based therapy to restore ciliary function in the lungs of people with DNAI1 gene mutations.
ReCode Therapeutics fosters a culture of exploration and belonging, where diverse perspectives and new ideas are valued. The company emphasizes collaboration, urgency in action, and autonomy to drive positive change. The team is motivated by the goal of delivering impactful medicines to patients and making a difference in the lives of those with genetic diseases.
ReCode Therapeutics was founded in 2015.
ReCode Therapeutics is active in the Rna Therapies, Genetic Medicines, Non-viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology markets.
ReCode Therapeutics has 11-50 employees.
ReCode Therapeutics hires globally with a remote-first approach, allowing employees to work from anywhere.
ReCode Therapeutics is not actively hiring at the moment. Check back later for new opportunities.
Yes, ReCode Therapeutics is a remote-first company.
ReCode Therapeutics's website is recodetx.com .
You can find ReCode Therapeutics on LinkedIn .
Remote companies like ReCode Therapeutics
Find your next opportunity with companies that specialize in Rna Therapies, Genetic Medicines, Non-viral Lipid Nanoparticles, and Genetic Respiratory Disease. Explore remote-first companies like ReCode Therapeutics that prioritize flexible work and home-office freedom.
Molecular Assemblies, Inc.
Enzymatic DNA synthesis for long, high-quality, sequence-specific DNA.
Tr1X
Developing regulatory T cell-based products for autoimmune and inflammatory diseases.
RubiconMD
Connecting primary care clinicians with board-certified specialists via eConsults to expand access to specialty care.
Apogee Therapeutics
A clinical-stage biotechnology company developing novel biologics for immunological and inflammatory disorders.
Olema Oncology
Develops cancer medicines, focusing on breast cancer and other endocrine-driven tumors.
Project: Career Search
Rev. 2026.2
[ Remote Jobs ]
Direct Access
We source jobs directly from 21,000+ company career pages. No intermediaries.
Discover Hidden Jobs
Unique jobs you won't find on other job boards.
Advanced Filters
Filter by category, benefits, seniority, and more.
Priority Job Alerts
Get timely alerts for new job openings every day.
Manage Your Job Hunt
Save jobs you like and keep a simple list of your applications.